Adaptimmune Therapeutics (ADAP)

• Market cap: $155M
• 1 day: 0.82%
• 5 days: 4.94%
• 1 month: -9.00%
• 3 months: -39.27%
• 6 months: -30.69%
• Year to date: -18.91%
• 1 year: 37.07%
• 5 years: -53.82%
• 10 years: -96.22%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.

Employees: 449

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

1,683% more call options, than puts

Call options by funds: $107K | Put options by funds: $6K

100% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 2 (+1) [Q3]

40% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 15

14% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 14

3% more funds holding

Funds holding: 76 [Q2] → 78 (+2) [Q3]

0.18% less ownership

Funds ownership: 10.07% [Q2] → 9.88% (-0.18%) [Q3]

4% less capital invested

Capital invested by funds: $150M [Q2] → $144M (-$6.46M) [Q3]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $1.50 148% upside
• Avg. target: $2.67 341% upside
• High target: $3.50 479% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Mizuho Graig Suvannavejh 41% 1-year accuracy 12 / 29 met price target	148% upside $1.50	Outperform Maintained	27 Nov 2024
HC Wainwright & Co. Arthur He 30% 1-year accuracy 11 / 37 met price target	479% upside $3.50	Buy Reiterated	19 Nov 2024
Guggenheim Michael Schmidt 26% 1-year accuracy 5 / 19 met price target	396% upside $3	Buy Maintained	15 Nov 2024